Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes

Journal of Molecular Medicine

Volumn 92, Issue 1, 2014, Pages 93-102

  Hara, Naoko ^a   Alkanani, Aimon K ^a   Dinarello, Charles A ^b   Zipris, Danny ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Histone deacetylase; Inflammation; Kilham rat virus; LEW1.WR1 rat; Type 1 diabetes

Indexed keywords

GIVINOSTAT; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; PROTEIN P40; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTESTINE FLORA; LYMPH NODE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; UPREGULATION; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; B-LYMPHOCYTES; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL TRACT; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IMMUNITY, INNATE; INFLAMMATION; LYMPHOID TISSUE; MALE; MICROBIOTA; PARVOVIRUS; RATS; T-LYMPHOCYTES;

EID: 84891858918     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1078-1     Document Type: Article

References (34)

1. Gianani R, Eisenbarth GS (2005) The stages of type 1A diabetes: 2005. Immunol Rev 204:232-249 (Pubitemid 40460505)
2. Zipris D (2009) Epidemiology of type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms. Clin Immunol 131:11-23
3. Zipris D (2010) Toll-like receptors and type 1 diabetes. Adv Exp Med Biol 654:585-610
4. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299 (Pubitemid 37361445)
5. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, Siegmund B (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176:5015-5022
6. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B et al (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164:10-21 (Pubitemid 40826758)
7. Chung YL, Lee MY, Wang AJ, Yao LF (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8:707-717 (Pubitemid 37527445)
8. Zipris D, Lien E, Xie JX, Greiner DL, Mordes JP, Rossini AA (2005) TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. The Journal of Immunology 174:131-142 (Pubitemid 40007399)
9. Zipris D, Lien E, Nair A, Xie JX, Greiner DL, Mordes JP, Rossini AA (2007) TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 178:693-701 (Pubitemid 46095141)
10. Lien E, Zipris D (2009) The role of toll-like receptor pathways in the mechanism of type 1 diabetes. Curr Mol Med 9:52-68
11. Zipris D, Hillebrands JL, Welsh RM, Rozing J, Xie JX, Mordes JP, Greiner DL, Rossini AA (2003) Infections that induce autoimmune diabetes in BBDR rats modulate CD4 + CD25+ T cell populations. J Immunol 170:3592-3602 (Pubitemid 36359227)
12. Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA, Wallace JE, Welsh RM (1991) Induction of type I diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 254:1010-1013 (Pubitemid 21917431)
13. Londono P, Komura A, Hara N, Zipris D (2010) Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol 135:401-411
14. Wolter TR, Wong R, Sarkar SA, Zipris D (2009) DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol 132:103-115
15. Wang L, de Zoeten EF, Greene MI, Hancock WW (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 8:969-981
16. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N et al (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777 (Pubitemid 44739521)
17. Ball-Goodrich LJ, Paturzo FX, Johnson EA, Steger K, Jacoby RO (2002) Immune responses to the major capsid protein during parvovirus infection of rats. J Virol 76:10044-10049 (Pubitemid 35006545)
18. Hirt B (2000) Molecular biology of autonomous parvoviruses. Contrib Microbiol 4:163-177
19. Dinarello CA (2006) Inhibitors of histone deacetylases as anti-inflammatory drugs. Ernst Schering Res Found Workshop:45-60
20. Dinarello CA, Fossati G, Mascagni P (2011) Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 17:333-352
21. Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D (2012) Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol 189:3805-3814
22. Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D (2013) The role of the intestinal microbiota in type 1 diabetes. Clin Immunol 146:112-119
23. Zipris D (2011) Innate immunity in type 1 diabetes. Diabetes Metab Res Rev 27:824-829
24. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, Dinarello CA (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 17:353-362
25. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E et al (2011) Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 186:3986-3996
26. Faraco G, Cavone L, Chiarugi A (2011) The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med 17:442-447
27. Vojinovic J, Damjanov N (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 17:397-403
28. Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63:1452-1458
29. Patel T, Patel V, Singh R, Jayaraman S (2011) Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol Cell Biol 89:640-649
30. Lewis EC, Blaabjerg L, Storling J, Ronn SG, Mascagni P, Dinarello CA, Mandrup-Poulsen T (2011) The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet beta cells in vivo and in vitro. Mol Med 17:369-377
31. Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, Krause A, Ivashkiv LB (2001) Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol 167:5395-5403 (Pubitemid 33009780)
32. Sobel DO, Newsome J (1997) Gamma interferon prevents diabetes in the BB rat. Clin Diagn Lab Immunol 4:764-768 (Pubitemid 27501421)
33. Larsen L, Tonnesen M, Ronn SG, Storling J, Jorgensen S, Mascagni P, Dinarello CA, Billestrup N, Mandrup-Poulsen T (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 50:779-789 (Pubitemid 46355819)
34. Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, Grunnet LG, Mandrup-Poulsen T (2011) Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 17:378-390